FlowER predicts ten-step pyrazole pathways consistent with known product selectivity
FlowER predicted two ten-step pathways to pyrazole products already reported in 2024 patents. Human researchers supplied acidic aqueous conditions omitted from the reaction database. Quantum-chemical calculations of intermediate energies favored the experimentally major product, consistent with the reported 8:2 product ratio; the kinetic interpretation assumes the Bell–Evans–Polanyi principle. This is a computational explanation of existing outcomes, with no new reaction experiment or claim of a previously unknown mechanism. Review covered the February 18, 2025 preprint results and the August 20 journal paper’s abstract, metadata and extended-data captions; the journal main text was not assessed.
Technology: FlowER (flow matching on bond-electron matrices)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Specific pyrazole-pathway predictions compared with known patent products and supplemented by calculated intermediate free energies.
- Still unknown: No new experimental confirmation; mechanistic priority not established. The kinetic argument assumes Bell–Evans–Polanyi reasoning; intermediate free energies are not measured transition-state barriers.
- AI role: FlowER generated candidate electron-redistribution pathways; authors supplied conditions and conducted quantum-chemical analysis.
Evidence sources: https://arxiv.org/html/2502.12979v1 · https://www.nature.com/articles/s41586-025-09426-9?error=cookies_not_supported
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 58 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.